Telomir Pharmaceuticals Featured in Local ABC Exclusive Showing Positive Outcomes of Proposed Age Reversal Pill in Dogs
Telomir Pharmaceuticals Featured in Local ABC Exclusive Showing Positive Outcomes of Proposed Age Reversal Pill in Dogs
Promising results with Telomir-1 Demonstrates Potential in Promoting Life Quality and Longevity in Senior Dogs
Telomir-1在促进老年犬生活质量和寿命方面展示了潜力,结果令人充满希望。
TAMPA, FL / ACCESSWIRE / August 20, 2024 / Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) ("Telomir" or the "Company"), a pre-clinical-stage company seeking to lead developments in longevity science through the treatment of age-related conditions, is proud to announce that its novel small molecule, Telomir-1, was recently featured in an exclusive local ABC television news segment highlighting promising "age reversal" outcomes in two senior dogs.
FLORIDA,TAMPA / ACCESSWIRE / 2024年8月20日 / 纳斯达克:TELO / Telomir制药公司(“Telomir”或“公司”)是一家临床前阶段的公司,通过治疗与年龄相关的疾病寻求领导发展长寿科学,非常自豪地宣布近期有关其创新型小分子Telomir-1的独家本地ABC电视新闻片段中亮相的有关两只老年犬“年龄逆转”结果的前景。
The use of Telomir-1 in these two dogs was observed by Telomir's special advisor Dr. Michael Roizen, the former Chief Wellness Officer of the Cleveland Clinic and a leader in age-related medicine. In this small compassionate use program, remarkable improvements in the health and vitality of the dogs after treatment with Telomir-1 was noted, offering a glimpse into the potential future applications for humans.
Telomir的特别顾问迈克尔·罗伊森博士(Michael Roizen)观察了这两只犬的使用情况,他曾是克利夫兰诊所的前首席健康官和年龄相关医学领域的领导者。在这个小型同情使用计划中,注意到了给予Telomir-1治疗后,这两只狗在健康和活力方面的显着提高,从而提供了一个关注未来应用于人类的可能性的一瞥。
In the segment, "ABC7 Exclusive: New study reveals promising results for age reversal pill on dogs," the transformative potential of Telomir-1 was showcased through the stories of Zeus and Benson, two senior dogs from Donte's Den rescue organization in Myakka City, Florida. After being treated with Telomir-1, both dogs exhibited significant improvements in their health conditions. Zeus, a 12-year-old German Shepherd, showed complete remission of terminal cancer, while Benson, a 12-year-old Newfoundland suffering from severe arthritis, regained his mobility, leading to what caretakers described as a miraculous recovery.
在片段“ABC7 Exclusive: New study reveals promising results for age reversal pill on dogs”中,Telomir-1的转型潜力通过佛罗里达州迈亚卡市Donte的Den救援组织的两只老年犬Zeus和Benson的故事展示出来。在接受Telomir-1治疗后,两只狗的健康状况都有了明显的改善。12岁的德国牧羊犬Zeus展现出终末癌症的完全缓解,而12岁的新地兰犬Benson患有严重的关节炎,恢复了他的运动能力,导致看护人员称之为奇迹般的康复。
Erez Aminov, the newly appointed Chairman CEO of Telomir Pharmaceuticals, expressed his commitment to advancing the science behind Telomir-1 and accelerating its path to market.
Telomir制药公司新任董事长兼首席执行官Erez Aminov表达了推进Telomir-1科学发展并加速其上市道路的承诺。
"The results seen in this study are a testament to the groundbreaking potential of Telomir-1. Our focus is on ensuring that we continue to push forward with the rigorous scientific research necessary to bring this promising treatment into human trials for particular indications, through the regulatory process and to ultimately to market as quickly and safely as possible. At Telomir, we are committed to transforming the future of longevity science, and these early findings bring us one step closer to achieving that goal," said Aminov.
Aminov说:“这项研究的结果证明了Telomir-1的突破性潜力。我们的重点是确保我们继续进行必要的严格科学研究,以将这种有前途的治疗方法引入人类试验,通过法规程序并尽快、安全地推向市场。在Telomir,我们致力于改变长寿科学的未来,这些早期发现让我们离实现这个目标更近了一步。”
Dr. Michael Roizen added, "The preliminary results we're seeing with Telomir-1 are very encouraging. By lengthening telomeres, we believe Telomir-1 can promote cell regeneration and potentially reverse several aspects of aging or age-related conditions. I'm excited to continue working with Telomir to explore the full potential of this innovative therapy."
Michael Roizen博士补充说:“我们正在看到Telomir-1的初步结果非常鼓舞人心。通过延长端粒,我们相信Telomir-1可以促进细胞再生并潜在地扭转衰老或与年龄相关的几个方面的状况。我很兴奋能继续与Telomir合作,探索这种创新疗法的全部潜力。”
To watch the full ABC7 exclusive segment, please visit:
观看完整的ABC7独家片段请访问:
About Telomir Pharmaceuticals, Inc.
关于Telomir Pharmaceuticals, Inc。
Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) is a pre-clinical stage pharmaceutical company seeking to lead development in longevity science in both humans and dogs. The Company is focused on the development of Telomir-1, a novel small molecule designed to lengthen the DNA's protective telomere caps, which are crucial in the aging process. The Company's goal is to explore the potential of Telomir-1 starting with ongoing research in animals and then in humans.
Telomir制药公司(纳斯达克:TELO)是一家临床前阶段的制药公司,旨在领导人类和犬类永久学发展。该公司专注于开发Telomir-1,这是一种新型小分子,旨在延长DNA的保护端粒帽,这在衰老过程中至关重要。该公司的目标是通过动物的持续研究,探索Telomir-1的潜力,然后在人类中进行人体试验。
Telomeres are the protective end caps of a chromosome made up of DNA sequences and proteins. As humans age, telomeres shorten, with metal reactivity accelerating the process, which presents humans and pet animals with an increased chance of contracting a number of degenerative and age-related diseases. Telomir's goal is to develop, gain regulatory approval for and commercialize Telomir-1, proposed to be dosed orally, with the broader aim of promoting longevity and enhancing overall quality of life.
端粒是由DNA序列和蛋白质组成的染色体保护端。“如人类年龄增长,端粒缩短,金属反应加速了这个过程,这使得人类和宠物动物有更大的机会患上多种退行性和与年龄相关的疾病。Telomir的目标是开发、获得监管批准和商业化Telomir-1,拟用于口服,从而促进寿命并提高整体生活质量。
The Nobel Assembly at Karolinska Institute (Sweden) awarded the Nobel Prize in Physiology or Medicine in 2009 for the discovery of how chromosomes are protected by telomeres and the enzyme telomerase.
卡罗林斯卡学院诺贝尔咨询委员会(瑞典)于2009年授予了生理学或医学诺贝尔奖,以表彰如何由端粒和端粒酶保护染色体的发现。
Telomir-1 is in preclinical development and has not yet been tested in humans. There is no assurance that Telomir-1 will proceed through development or will ultimately receive FDA approval for marketing.
Telomir-1正在进行临床前开发,尚未在人体上测试。不能保证Telomir-1将通过开发或最终获得FDA批准进行营销。
Cautionary Note Regarding Forward-Looking Statements
关于前瞻性声明的谨慎说明
This press release, statements of Telomir Pharmaceuticals' management or advisors related thereto and the statements contained in the news story linked in this release contain "forward-looking statements," which are statements other than historical facts made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements may be identified by words such as "aims," "anticipates," "believes," "could," "estimates," "expects," "forecasts," "goal," "intends," "may," "plans," "possible," "potential," "seeks," "will," and variations of these words or similar expressions that are intended to identify forward-looking statements. Any such statements in this press release that are not statements of historical fact may be deemed to be forward-looking statements. These forward-looking statements include, without limitation, statements regarding (i) the anticipated benefits of the compassion use program described herein, (ii) anticipated timelines for preclinical and clinical testing of Telomir-1 and (iii) the potential therapeutic benefits of Telomir-1 generally.
本新闻稿,Telomir制药公司管理层或其顾问相关陈述以及本新闻稿中链接的新闻故事中的陈述均包含“前瞻性陈述”,这些陈述并非历史事实,根据1933年修订版证券法第27A条和1934年修订版证券交易法第21E条的安全港条款进行制定。这些语句可以通过诸如“目的”、“预计”、“相信”、“可能”、“预估”、“期望”、“预测”、“目标”、“有意”、“可能”、“潜在”、“寻求”、“将”以及这些词或类似表述进行识别,旨在识别前瞻性陈述。本新闻稿中的任何不是历史事实的陈述都可能被认为是前瞻性陈述。这些前瞻性陈述包括(1)本新闻稿中描述的同情使用计划的预期益处;(2) Telomir-1进行临床前和临床试验的预期时间表;以及(3) Telomir-1的潜在治疗效益总体而言。
Any forward-looking statements in this press release are based on Telomir's current expectations, estimates and projections only as of the date of this release and are subject to a number of significant risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, the potential use of the data from our studies, our ability to develop and commercialize Telomir-1 for specific indications and safety of Telomir-1. These and other risks concerning Telomir's programs and operations are described in additional detail in its Annual Report on Form 10-K for the fiscal year ended December 31, 2023, which is on file with the SEC. Telomir explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law.
本新闻稿中的任何前瞻性陈述仅基于Telomir在本稿发布日期的当前期望、估计和投影,并受到许多重大风险和不确定性的影响,这些重大风险和不确定性可能导致实际结果与在这些前瞻性陈述中设定或暗示的结果实质性地不同或对结果产生不利影响。这些关于Telomir计划和运营的风险和不确定性的详细描述在其于2023年12月31日结束的财年第10-K年度报告中以及提交给SEC,目前可供查询。Telomir明确否认除法律规定外的任何更新前瞻性陈述的义务。
Readers are cautioned that the statements made by third parties in the news story linked in this release represent the views of such third parties and not necessarily the views of Telomir Pharmaceuticals.
读者应当注意到本文档链接的新闻故事中的第三方发表的言论代表了这些第三方的观点,而不一定是Telomir制药公司的观点。
Contact Information
联系信息
Helga Moya
info@telomirpharma.com
(813) 864-2558
Helga Moya
info@telomirpharma.com
(813) 864-2558
SOURCE: Telomir Pharmaceuticals, Inc.
来源:Telomir Pharmaceuticals,Inc。